Romidepsin: in the treatment of T-cell lymphoma
LPH Yang - Drugs, 2011 - Springer
Romidepsin is a histone deacetylase inhibitor with high inhibitory activity for class I histone
deacetylases. Intravenous romidepsin is indicated in the US for the treatment of adult …
deacetylases. Intravenous romidepsin is indicated in the US for the treatment of adult …
Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma
KA Lyseng-Williamson, LP Yang - American journal of clinical dermatology, 2012 - Springer
Intravenous romidepsin (Istodax®), a histone deacetylase inhibitor, is indicated in the US for
the treatment of cutaneous T-cell lymphoma (CTCL) in adults who have received at least …
the treatment of cutaneous T-cell lymphoma (CTCL) in adults who have received at least …
Romidepsin for the treatment of T-cell lymphomas
AL McGraw - American journal of health-system pharmacy, 2013 - academic.oup.com
Purpose The pharmacology, pharmacokinetic and pharmacodynamic properties, and
clinical data on a novel therapy for the treatment of cutaneous or peripheral T-cell lymphoma …
clinical data on a novel therapy for the treatment of cutaneous or peripheral T-cell lymphoma …
The discovery and development of romidepsin for the treatment of T-cell lymphoma
P Smolewski, T Robak - Expert opinion on drug discovery, 2017 - Taylor & Francis
Introduction: Romidepsin is a potent and selective inhibitor of histone deacetylases (HDCAi).
It is also the only bicyclic inhibitor to undergo clinical assessment and is considered a …
It is also the only bicyclic inhibitor to undergo clinical assessment and is considered a …
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
Purpose Romidepsin is a structurally unique, potent class 1 selective histone deacetylase
inhibitor. The primary objective of this international, pivotal, single-arm, phase II trial was to …
inhibitor. The primary objective of this international, pivotal, single-arm, phase II trial was to …
Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma
M Kim, LA Thompson, SD Wenger… - Annals of …, 2012 - journals.sagepub.com
Objective: To evaluate the efficacy and safety of romidepsin in refractory cutaneous T-cell
lymphoma (CTCL). Data Sources: An English-language literature search of PubMed and …
lymphoma (CTCL). Data Sources: An English-language literature search of PubMed and …
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
Background Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone
deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of …
deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of …
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma
RL Piekarz, R Frye, M Turner, JJ Wright… - Journal of clinical …, 2009 - ascopubs.org
Purpose Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic
agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of …
agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of …
Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study
D Maruyama, K Tobinai, M Ogura, T Uchida… - International journal of …, 2017 - Springer
This phase I/II multicenter study evaluated romidepsin treatment in Japanese patients with
relapsed/refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma …
relapsed/refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma …
[HTML][HTML] Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).
Background: The histone deacetylase (HDAC) inhibitors are a class of epigenetic agents
undergoing clinical testing. HDAC inhibitors modulate expression of genes involved in cell …
undergoing clinical testing. HDAC inhibitors modulate expression of genes involved in cell …